Company Overview
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Herzliya, Israel.
Recent Developments
- 5-Year Trend Long-term compounding — profit CAGR -139.0%.
Growth & Price Performance
Compounded Profit Growth
| 5 Years: | -139.00% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | -49.28% |
| 6 Months: | -16.07% |
| 3 Months: | -27.69% |
| 1 Month: | +13.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)50.16 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Earnings shrank at -139.0% CAGR over 5 years.
- Trading 65.6% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | XTLB XTL Biopharmaceuticals Ltd. | 2.82 | -7.83 | $6.93M | 0.00% | - | -29.30% | - | -139.00% |
| 2 | LLY Eli Lilly and Company SPX | 1,148.84 | 40.85 | $1.02T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 256.35 | 29.74 | $617.09B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 250.94 | 122.41 | $443.36B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 414.40 | 31.23 | $376.34B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 130.20 | 36.68 | $321.57B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 169.64 | 26.30 | $263.09B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 574.30 | 31.54 | $213.42B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 385.16 | 26.78 | $207.87B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 |
|---|---|
| Revenue | 289.00K |
| Cost of Revenue | 332.00K |
| Gross Profit | -43.00K |
| Operating Expenses | 769.00K |
| Operating Income | -812.00K |
| EBITDA | -479.00K |
| Interest Expense | -94.00K |
| Pretax Income | -385.00K |
| Tax Provision | - |
| Net Income | -255.00K |
| Diluted EPS | - |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | 0 | 0 | 0 | 0 |
| Gross Profit | - | 0 | 0 | 0 | 0 |
| Operating Expenses | - | 880.00K | 765.00K | 775.00K | 1.38M |
| Operating Income | - | -880.00K | -765.00K | -775.00K | -1.38M |
| EBITDA | - | -1.35M | -1.78M | 467.00K | -752.00K |
| Interest Expense | - | 0 | 0 | 28.00K | 7.00K |
| Pretax Income | - | -1.35M | -1.78M | 240.00K | -759.00K |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -1.35M | -1.78M | -1.03M | -6.97M |
| Diluted EPS | -0.15 | -0.80 | -1.20 | -0.80 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 4.19M | 2.43M | 8.55M | 166.00K |
| Current Assets | - | 3.81M | 2.05M | 1.34M | 166.00K |
| Cash & Equivalents | - | 2.09M | 1.40M | 371.00K | 76.00K |
| Inventory | - | - | - | - | - |
| Receivables | - | - | 0 | 99.00K | 0 |
| Total Liabilities | - | 187.00K | 206.00K | 3.12M | 420.00K |
| Current Liabilities | - | 187.00K | 206.00K | 2.21M | 420.00K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | 138.00K | 269.00K |
| Total Equity | - | 4.00M | 2.22M | 5.43M | -254.00K |
| Shares Outstanding | - | 544.91M | 544.91M | 881.39M | 1.32B |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -901.00K | -707.00K | -1.62M | -1.02M |
| Investing Cash Flow | - | 36.00K | 41.00K | -844.00K | 522.00K |
| Financing Cash Flow | - | 0 | 0 | 1.45M | 208.00K |
| Capital Expenditure | - | - | - | -54.00K | - |
| Free Cash Flow | - | -901.00K | -707.00K | -1.67M | -1.02M |
| Net Change in Cash | - | -865.00K | -666.00K | -1.01M | -295.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -33.7% | -80.3% | -18.9% | 2,743.7% |
| ROCE % | - | -22.0% | -34.5% | -12.2% | 543.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Noked Israel Ltd. | 2.10% | 49.72K | $140.22K |
| 2 | Smartharvest Portfolios, LLC | 0.56% | 13.35K | $37.65K |
| 3 | Rhumbline Advisers | 0.25% | 5.99K | $16.88K |
| 4 | Gamma Investing LLC | 0.05% | 1.21K | $3.42K |
| 5 | Tower Research Capital LLC (TRC) | 0.01% | 244 | $688 |
| 6 | Morgan Stanley | - | 10 | $28 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for XTLB
XTLB — Frequently Asked Questions
What is the current share price of XTL Biopharmaceuticals Ltd. (XTLB)?
As of 2026-08-02 19:16 PDT, XTL Biopharmaceuticals Ltd. (XTLB) trades at $2.82 on NasdaqCM. Its 52-week range is $2.06 to $8.20.
What is the market capitalisation of XTLB?
XTL Biopharmaceuticals Ltd. (XTLB) has a market capitalisation of $6.93M on NasdaqCM.
What is the P/E ratio of XTLB?
XTLB trades at a trailing price-to-earnings (P/E) ratio of -7.83. The industry average P/E is 27.41.
What is the return on equity (ROE) of XTLB?
XTLB has a return on equity (ROE) of -29.30%.
Is XTLB a good stock to buy?
This page provides a data-driven analysis of XTL Biopharmaceuticals Ltd. (XTLB), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.